Trial Profile
A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination With High or Low-Dose Radiation in Metastatic Colorectal and NSCLC
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- 04 Jan 2024 Planned End Date changed from 31 Dec 2023 to 2 Jan 2025.
- 03 Jan 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 03 Jan 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.